Leda P Mannent
Overview
Explore the profile of Leda P Mannent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1528
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sindher S, Nadeau K, Chinthrajah R, Leflein J, Begin P, Ohayon J, et al.
Allergy
. 2024 Dec;
80(1):227-237.
PMID: 39673452
Background: Peanut allergy is a potentially life-threatening food allergy in children. This study explored whether dupilumab, a human monoclonal immunoglobulin (Ig)G4 antibody that blocks the activity of interleukin (IL)-4/IL-13, improved...
2.
Chinthrajah R, Sindher S, Nadeau K, Leflein J, Spergel J, Petroni D, et al.
Allergy
. 2024 Dec;
80(3):827-842.
PMID: 39673367
Background: Peanut allergy is a common, life-threatening food allergy in children. We evaluated whether dupilumab, which blocks the activity of interleukin (IL)-4/IL-13, enhances the efficacy of oral immunotherapy (OIT) AR101...
3.
Bachert C, Khan A, Hopkins C, Han J, Fokkens W, Mannent L, et al.
Ann Allergy Asthma Immunol
. 2024 Sep;
134(1):61-69.e12.
PMID: 39343385
Background: Frequently reported outcomes of clinical trials in chronic rhinosinusitis with nasal polyps (CRSwNP) may have limited relatability for patients. Objective: To enhance the patient relatability of outcomes in dupilumab...
4.
Gayvert K, Desrosiers M, Laidlaw T, Mannent L, Patel K, Horowitz J, et al.
J Allergy Clin Immunol
. 2024 Jun;
154(3):619-630.
PMID: 38880251
Background: There is evidence of pathophysiologic diversity in chronic rhinosinusitis with nasal polyps (CRSwNP), but data characterizing the molecular endotypes of CRSwNP and their association with treatment are lacking. Objective:...
5.
Maurer M, Casale T, Saini S, Ben-Shoshan M, Gimenez-Arnau A, Bernstein J, et al.
J Allergy Clin Immunol
. 2024 Mar;
154(1):184-194.
PMID: 38431226
Background: Chronic spontaneous urticaria (CSU) is a chronic inflammatory disease characterized by recurrent pruritic wheals (hives) and/or angioedema. Patients with CSU could remain symptomatic despite standard-of-care H antihistamines (H1-AH) or...
6.
Papi A, Castro M, Corren J, Pavord I, Tohda Y, Altincatal A, et al.
Respir Med
. 2024 Jan;
224:107535.
PMID: 38272376
Background: TRAVERSE (NCT02134028), a phase 3 open-label extension study, assessed dupilumab safety and efficacy in patients with asthma aged ≥12 years who completed a previous dupilumab asthma study. This analysis...
7.
Bacharier L, Pavord I, Maspero J, Jackson D, Fiocchi A, Mao X, et al.
J Allergy Clin Immunol
. 2024 Jan;
154(1):101-110.
PMID: 38272375
Background: Blood eosinophils and fractional exhaled nitric oxide (Feno) are prognostic biomarkers for exacerbations and predict lung function responses to dupilumab in adolescents and adults with asthma. Objective: We evaluated...
8.
Bacharier L, Guilbert T, Katelaris C, Deschildre A, Phipatanakul W, Liu D, et al.
J Allergy Clin Immunol Pract
. 2023 Dec;
12(4):948-959.
PMID: 38092225
Background: Uncontrolled asthma in growing children can impair lung growth that may lead to adverse complications in later life. Dupilumab, a human monoclonal antibody, blocks the shared receptor for IL-4...
9.
Bacharier L, Maspero J, Katelaris C, Fiocchi A, Gagnon R, de Mir I, et al.
Lancet Respir Med
. 2023 Nov;
12(1):45-54.
PMID: 37956679
Background: Dupilumab efficacy and safety in children aged 6-11 years with uncontrolled, moderate-to-severe asthma were shown in the VOYAGE study-a 52-week, multinational, multicentre, phase 3 randomised, double-blind, placebo-controlled trial. We...
10.
Wechsler M, Souza-Machado A, Xu C, Mao X, Kapoor U, Khokhar F, et al.
J Allergy Clin Immunol Glob
. 2023 Oct;
1(1):9-15.
PMID: 37780074
Background: The safety and tolerability of live attenuated vaccines in patients administered dupilumab for moderate-to-severe asthma have not been previously evaluated. During the LIBERTY ASTHMA TRAVERSE open-label extension study (ClinicalTrials.gov...